Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALDX Aldeyra Therapeutics	$5.03 -2.5%	$3.16	$1.14 ▼ $7.20	$309.06M	0.9	889,531 shs	1.92 million shs
CADL Candel Therapeutics	$6.92 +1.0%	$5.45	$3.79 ▼ $14.60	$343.20M	-0.91	1.51 million shs	1.28 million shs
CNTB Connect Biopharma	$1.86 +14.8%	$0.97	$0.51 ▼ $1.89	$90.01M	-0.2	65,543 shs	529,485 shs
INZY Inozyme Pharma	$4.00	$3.71	$0.72 ▼ $6.24	$258.25M	2.27	947,561 shs	N/A

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALDX Aldeyra Therapeutics	+3.82%	+14.16%	+70.86%	+135.62%	+20.00%
CADL Candel Therapeutics	+9.60%	+12.48%	+32.75%	+49.89%	-6.04%
CNTB Connect Biopharma	+10.96%	+48.81%	+65.32%	+119.16%	+25.58%
INZY Inozyme Pharma	0.00%	0.00%	+0.76%	+335.02%	-30.68%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALDX Aldeyra Therapeutics	2.6059 of 5 stars	3.5	3.0	2.9	0.8	0.6
CADL Candel Therapeutics	2.4884 of 5 stars	3.6	1.0	3.4	1.7	0.6
CNTB Connect Biopharma	2.6041 of 5 stars	3.5	3.0	2.5	2.5	0.0
INZY Inozyme Pharma	3.5201 of 5 stars	4.2	4.0	2.7	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALDX Aldeyra Therapeutics	3.00	Buy	$9.50	88.87% Upside
CADL Candel Therapeutics	3.20	Buy	$22.00	217.92% Upside
CNTB Connect Biopharma	3.00	Buy	$7.00	276.34% Upside
INZY Inozyme Pharma	2.44	Hold	$11.75	193.75% Upside

Current Analyst Ratings Breakdown

Latest CNTB, INZY, ALDX, and CADL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/9/2025	CADL Candel Therapeutics	Brookline Capital Management Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/30/2025	CADL Candel Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$23.00
6/12/2025	CNTB Connect Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy ➝ Buy	$7.00
5/19/2025	ALDX Aldeyra Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
5/16/2025	INZY Inozyme Pharma	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/16/2025	INZY Inozyme Pharma	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/16/2025	INZY Inozyme Pharma	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Moderate Buy ➝ Hold
5/16/2025	INZY Inozyme Pharma	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$4.00
5/16/2025	INZY Inozyme Pharma	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold	$15.00 ➝ $4.00
5/14/2025	INZY Inozyme Pharma	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $12.00

(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALDX Aldeyra Therapeutics	N/A	N/A	N/A	N/A	$1.19 per share	N/A
CADL Candel Therapeutics	$120K	2,889.10	N/A	N/A	$1.41 per share	4.91
CNTB Connect Biopharma	$26.03M	3.97	N/A	N/A	$1.67 per share	1.11
INZY Inozyme Pharma	N/A	N/A	N/A	N/A	$0.90 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALDX Aldeyra Therapeutics	-$55.85M	-$0.97	N/A	N/A	N/A	N/A	-72.58%	-52.32%	7/30/2025 (Estimated)
CADL Candel Therapeutics	-$55.18M	-$1.34	N/A	N/A	N/A	N/A	-136.74%	-63.13%	8/12/2025 (Estimated)
CNTB Connect Biopharma	-$15.63M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	9/5/2025 (Estimated)
INZY Inozyme Pharma	-$102.02M	-$1.69	N/A	N/A	N/A	N/A	-159.93%	-82.48%	8/5/2025 (Estimated)

Latest CNTB, INZY, ALDX, and CADL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	CADL Candel Therapeutics	-$0.17	N/A	N/A	N/A	N/A	N/A
8/7/2025	Q2 2025	ALDX Aldeyra Therapeutics	-$0.24	N/A	N/A	N/A	N/A	N/A
8/5/2025	Q2 2025	INZY Inozyme Pharma	-$0.36	N/A	N/A	N/A	N/A	N/A
5/15/2025	Q1 2025	CNTB Connect Biopharma	-$0.26	-$0.19	+$0.07	-$0.19	N/A	N/A
5/14/2025	Q1 2025	ALDX Aldeyra Therapeutics	-$0.25	-$0.17	+$0.08	-$0.17	($0.80) million	N/A
5/14/2025	Q1 2025	INZY Inozyme Pharma	-$0.43	-$0.44	-$0.01	-$0.44	N/A	N/A
5/13/2025	Q1 2025	CADL Candel Therapeutics	-$0.24	$0.13	+$0.37	$0.13	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALDX Aldeyra Therapeutics	N/A	N/A	N/A	N/A	N/A
CADL Candel Therapeutics	N/A	N/A	N/A	N/A	N/A
CNTB Connect Biopharma	N/A	N/A	N/A	N/A	N/A
INZY Inozyme Pharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALDX Aldeyra Therapeutics	0.24	6.49	6.49
CADL Candel Therapeutics	0.01	4.64	4.64
CNTB Connect Biopharma	0.01	10.25	10.25
INZY Inozyme Pharma	0.65	2.19	2.19

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALDX Aldeyra Therapeutics	59.71%
CADL Candel Therapeutics	13.93%
CNTB Connect Biopharma	58.72%
INZY Inozyme Pharma	88.30%

Insider Ownership

Company	Insider Ownership
ALDX Aldeyra Therapeutics	9.60%
CADL Candel Therapeutics	16.60%
CNTB Connect Biopharma	22.60%
INZY Inozyme Pharma	12.18%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALDX Aldeyra Therapeutics	10	59.90 million	54.15 million	Optionable
CADL Candel Therapeutics	60	50.10 million	41.79 million	Optionable
CNTB Connect Biopharma	110	55.56 million	43.00 million	Optionable
INZY Inozyme Pharma	50	64.56 million	56.70 million	Optionable

CNTB, INZY, ALDX, and CADL Headlines

Recent News About These Companies

Brokerages Set Inozyme Pharma, Inc. (NASDAQ:INZY) Target Price at $11.75

July 7, 2025 | americanbankingnews.com

Inozyme Pharma (NASDAQ:INZY) Stock Rating Upgraded by Wall Street Zen

July 5, 2025 | marketbeat.com

Inozyme Pharma, Inc. (NASDAQ:INZY) Given Consensus Recommendation of "Hold" by Analysts

July 4, 2025 | marketbeat.com

Inozyme Pharma Inc News (INZY) - Investing.com

July 2, 2025 | investing.com

BioMarin Announces Completion of Acquisition of Inozyme

July 1, 2025 | prnewswire.com

Inozyme Pharma Inc Ordinary Shares

June 21, 2025 | morningstar.comM

Inozyme Pharma, Inc. Announces Postponement of 2025 Annual Meeting of Stockholders

June 20, 2025 | globenewswire.com

Inozyme Pharma Reports Increased Loss Amid Strategic Focus

June 9, 2025 | tipranks.com

BMRN to Acquire Inozyme Pharma

May 22, 2025 | finance.yahoo.com

INOZYME PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inozyme Pharma, Inc. - INZY

May 21, 2025 | businesswire.com

StockWatch: With Inozyme Buyout, BioMarin Pursues Growth via M&A

May 18, 2025 | genengnews.comG

Jefferies Downgrades Inozyme Pharma (INZY)

May 17, 2025 | msn.com

Needham Downgrades Inozyme Pharma (INZY)

May 17, 2025 | msn.com

Leerink bullish on BioMarin following Inozyme deal, expects additional BD

May 17, 2025 | finance.yahoo.com

Inozyme Shares More Than Double in Surge Toward BioMarin's Buyout Price

May 16, 2025 | marketwatch.com

BioMarin to buy rare disease drugmaker Inozyme for $270M

May 16, 2025 | biopharmadive.comB

BioMarin stock rises following Inozyme Pharma acquisition

May 16, 2025 | in.investing.com

BioMarin to Acquire Inozyme Pharma for $270M

May 16, 2025 | contractpharma.comC

BioMarin buys Inozyme for $270 million

May 16, 2025 | thepharmaletter.comT

BioMarin to buy enzyme therapy developer Inozyme in $270M all-cash deal

May 16, 2025 | msn.com

Inozyme Stock Rockets 179% After BioMarin Agrees To Acquire The Company For $270M: Retail Sentiment Brightens

May 16, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNTB, INZY, ALDX, and CADL Company Descriptions

Aldeyra Therapeutics NASDAQ:ALDX

$5.03 -0.13 (-2.52%)

Closing price 04:00 PM Eastern

Extended Trading

$5.06 +0.02 (+0.50%)

As of 07:51 PM Eastern

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company's clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer.

Candel Therapeutics NASDAQ:CADL

$6.92 +0.07 (+1.02%)

Closing price 04:00 PM Eastern

Extended Trading

$6.93 +0.01 (+0.14%)

As of 07:51 PM Eastern

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.

Connect Biopharma NASDAQ:CNTB

$1.86 +0.24 (+14.81%)

Closing price 04:00 PM Eastern

Extended Trading

$1.89 +0.03 (+1.61%)

As of 07:48 PM Eastern

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.

Inozyme Pharma NASDAQ:INZY

$4.00 0.00 (0.00%)

As of 07/1/2025

Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time